Archives
-
Zoledronic Acid: From Assay Design to Mechanism
2026-08-23
Explore how Zoledronic Acid can be studied through mechanism-aware cancer and bone-disease assays. This guide translates a recent causal immunology framework into practical decisions for dose–time mapping, apoptosis validation, and evidence-limited cross-domain interpretation.
-
Carbapenemase Transmission in Resistant E. cloacae
2026-08-22
A 2025 multicenter study examined 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong and found that carbapenemase-encoding genes were common, frequently plasmid-associated, and highly transferable. Its integrated analysis of gene location, conjugation, mobile genetic elements, and strain relatedness provides a practical framework for studying carbapenem-resistant bacterial infections and hospital transmission.
-
Fingolimod: Reframing T-Cell Trafficking
2026-08-22
Fingolimod (FTY720) offers translational researchers a controlled way to interrogate S1P-dependent lymphocyte movement, while a recent magnetic bispecific nano-antibody study illustrates how immune-cell positioning is becoming a central design variable in solid-tumor engineering. This article outlines how to use Fingolimod as an assay tool without overstating its readiness as a CAR-T combination therapy.
-
MLN2238: Proteasome β5 Inhibition Workflows
2026-08-21
MLN2238 combines nanomolar proteasome β5 activity with a reversible mechanism suited to dose-response, washout, apoptosis, and proteotoxic-stress assays. This guide translates its oncology use into practical workflows for multiple myeloma, lymphoma, drug-resistance, and ROS/JNK–CREB studies.
-
Optimized hiPSC Differentiation for Functional Platelets
2026-08-20
Yue et al. developed an optimized embryoid body-based protocol that improves megakaryocyte production and functional platelet release from human induced pluripotent stem cells. The strategy combines higher starting cell input, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds to shorten production time, increase yield, and reduce cost.
-
EdU Imaging Kits (Cy5) in Wound-Healing Biology
2026-08-20
EdU Imaging Kits (Cy5) provide a morphology-preserving way to measure DNA synthesis in epithelial wound models. This article translates recent DCPS findings in diabetic foot ulcers into practical imaging and flow-cytometry assay decisions.
-
Tauroursodeoxycholic Acid: ER Stress Workflows
2026-08-19
Tauroursodeoxycholic Acid provides a practical chemical-chaperone strategy for connecting ER stress, mitochondrial instability, inflammation, and apoptosis in cell and tissue models. This workflow-focused guide shows how to position TUDCA as a pharmacological comparator in neuroinflammation studies while extending its use to metabolic and regenerative research.
-
Lumiracoxib and the Timing of COX-2 Biology
2026-08-19
A translational framework for using Lumiracoxib to distinguish protective from maladaptive COX-2 signaling in muscle injury, with emphasis on temporal design, vascular readouts, assay controls, and research-grade compound handling.
-
Telmisartan in Cardiac Hypertrophy Research
2026-08-18
Telmisartan provides an AT1-receptor-centered control for Ang II cardiac hypertrophy models, helping researchers distinguish upstream receptor blockade from downstream RIP3/CaMKII regulation. This guide covers DMSO preparation, assay design, pathway readouts, comparative use with isochlorogenic acid A, and troubleshooting for reproducible cardiovascular disease research.
-
High-Throughput Measurement of Fractional Killing
2026-08-18
Inde, Rodencal, and Dixon present a high-throughput microscopy protocol for measuring drug-induced fractional killing over time rather than relying on a single bulk viability endpoint. The workflow combines nuclear fluorescent labeling of live cells with dead-cell imaging, enabling parallel comparison of hundreds of treatment conditions and analysis of variable responses to MEK1/2 inhibitors.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Precise Editing
2026-08-17
Build transient CRISPR workflows around Cap1-capped, m1Ψ-modified Cas9 mRNA for efficient genome editing in mammalian cells. This practical guide connects RNA handling, dose optimization, nuclear-export biology, and troubleshooting to improve reproducibility without overstating product-specific performance.
-
MOG (35-55) for Reproducible EAE Research
2026-08-17
Build more consistent experimental autoimmune encephalomyelitis models with a defined myelin oligodendrocyte glycoprotein peptide and a workflow that connects disease scoring to mechanistic neuroinflammation assays. This guide translates the latest PARP7–STAT1/STAT2 findings into practical choices for multiple sclerosis research, dose selection, sample handling, and troubleshooting.
-
TH287: Turning Oxidative Stress Into Radiosensitivity
2026-08-16
A translational analysis of TH287 as an MTH1 inhibitor for cancer research, focusing on oxidized nucleotide sanitization, radiation scheduling, DNA damage biology, and the evidence needed to move from cell-based radiosensitization to a credible therapeutic hypothesis.
-
PARP7–STAT1/2 Control of EAE
2026-08-15
A 2025 Cell Reports study identifies PARP7 as a suppressor of type I interferon signaling rather than interferon production. By linking STAT1/STAT2 mono-ADP-ribosylation to ubiquitination and p62-dependent autophagic degradation, the work provides a mechanistic explanation for why PARP7 inhibition alleviates experimental autoimmune encephalomyelitis in mice.
-
Protoporphyrin IX at the Heme-Ferroptosis Interface
2026-08-14
Protoporphyrin IX is more than a heme precursor: it is a photodynamic compound and a powerful experimental lens for studying iron-dependent biology. This article connects its chemistry to ferroptosis assay design while clarifying what recent hepatocellular carcinoma evidence does—and does not—demonstrate.